Pressroom

Press Room (2014 – )

Research Article, April 2017

This collaborative study was published in Biochimica et Biophysica Acta (BBA)-General Subjects.

Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.

Biochim Biophys Acta. 2017 Apr;1861(4):910-921.

 

Boulder Peptide Symposium, September 26-29, 2016

CDG Therapeutics was invited to present at the Boulder Peptide Symposium (http://boulderpeptide.org), Boulder, Colorado.

Title: p28, a Non-toxic, Orphan/Rare Pediatric Disease Designated, Cell Penetrating Peptide for the Treatment of Pediatric Brain Tumors

 

Research Article, March 2016

A national, multi institutional, Phase Ia,b clinical trial of p28 as a single agent in pediatric patients with recurrent or progressive CNS tumors sponsored by the Pediatric Brain Tumor Consortium (PBTC-041) and the NCI-CTEP was published in Neuro-Oncology.

Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Neuro Oncol., 2016 Sep;18(9):1319-25

 

Press release, March 2016

On March 1, 2016 CDG Therapeutics Inc.,  a clinical stage biopharmaceutical company focused on discovering and developing novel cell-penetrating therapeutic peptides for cancers and allied diseases, released that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CDG28 (p28), the Company’s lead candidate after a successful Phase I trial in progressive or refractory pediatric brain tumors. CDG28 readily crosses the blood brain barrier, preferentially enters brain tumor cells and exerts efficacy with no significant, drug related, adverse effects. The FDA also designated CDG28 for the treatment of rare pediatric diseases: diffuse intrinsic pontine glioma (DIPG).

 

Research Article, February 2016

Preclinical study on p28 in combination with DNA damaging and anti-mitotic agents was published in Cancer Research, American Association for Cancer Research.

p28-mediated Activation of p53 in G2/M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.

Cancer Res. 2016 Feb 26; 76(8): 2354-2365

 

Boulder Peptide Symposium, September 2015

CDG Therapeutics presented their recent pre-clinical and clinical results at the Boulder Peptide Symposium, Boulder, Colorado.

 

American Society of Clinical Oncology (ASCO), May 2015

A final report of pediatric Phase I clinical trial of p28 presented at the 2015 meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL.

Title: Phase 1 Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Children with Recurrent or Progressive CNS Tumors: A Final Report from the Pediatric Brain Tumor Consortium. Abstract #10059

http://abstracts.asco.org/156/AbstView_156_152030.html

 

Research Article, January 2015

This collaborative study was published in Molecular Pharmaceutics, American Chemical Society.

Chirality Switching within an Anionic Cell-Penetrating Peptide Inhibits Translocation without Affecting Preferential Entry.

Mol Pharm. 2015 Jan 5;12(1):140-9. doi: 10.1021/mp500495u. Epub 2014 Dec 5.

 

16th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 2014

The pediatric brain tumor consortium (PBTC) presented an interim report of pediatric Phase I clinical trial of p28 at ISPNO, Singapore.

Title: Phase 1 trial of p28 (NSC745104), a non-HDM2 mediated inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors:  a report from the pediatric brain tumor consortium.

 

IBC’s 16th Annual TIDES, May 2014

CDG Therapeutics was invited to present at IBC’s annual TIDES meeting, Providence, Rhode Island.
Title: p28, a first-in-class, non-HDM2-mediated peptide inhibitor of p53 Ubiquitination.